
Opinion|Videos|August 21, 2024
PDTs as a Part of Integrative Care and Evaluating Patient Outcomes With PDTs
Author(s)Arwen Podesta, MD
Arwen Podesta, MD, examines the role of photodynamic therapies in integrative care and assess how they impact patient outcomes.
Advertisement
Episodes in this series

- What are some of the benefits of prescription digital therapeutics (PDTs) for patients and providers?
- How can PDTs help improve patient adherence to treatment?
- How can PDTs help improve patient engagement and self-management of their health condition?
Advertisement
Related to this article

Prioritizing referral completion as much as referral generation will equip organizations to measure results and improve health outcomes.

Daiichi Sankyo and Merck pulled their bid for accelerated approval of I-DXd in small cell lung cancer after the FDA found phase 2 data fell short.

In this discussion, Chad Hatfield, Pharm.D., M.H.A., BCPS, shares his perspective on the evolving role of pharmacy services and the value of collaboration across health care.

CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.

Dunn of NeosRx says a 340B shift from discounts to rebates likely won't affect rebate erosion affecting plan sponsors.

Five transcranial magnetic stimulation sessions in one day improved processing speed in adults with schizophrenia, which holds promise for future treatment possibilities, according to researcher Heather Burrell Ward, M.D.

Imaging has been associated with four of the five most prevalent low-value services among Medicare beneficiaries.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer
2
Why consumers still can’t comparison shop for medication
3
The hidden costs of routine radiology and how they can be addressed
4
A conversation with Chad Hatfield, Pharm.D., M.H.A., BCPS, about pharmacy expansion, clinical specialization and regulatory readiness
5




